PDZK1 is Correlated with DCE-MRI Perfusion Parameters in High-grade Glioma

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2024 May 1

PMID 38692010

Authors

Yi Zhang

Feng Wang

Yongli Huang

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigated the relationship between PDZK1 expression and Dynamic Contrast-Enhanced MRI (DCE-MRI) perfusion parameters in High-Grade Glioma (HGG).

Methods: Preoperative DCE-MRI scanning was performed on 80 patients with HGG to obtain DCE perfusion transfer coefficient (K), vascular plasma volume fraction (v), extracellular volume fraction (v), and reverse transfer constant (k). PDZK1 in HGG patients was detected, and its correlation with DCE-MRI perfusion parameters was assessed by the Pearson method. An analysis of Cox regression was performed to determine the risk factors affecting survival, while Kaplan-Meier and log-rank tests to evaluate PDZK1's prognostic significance, and ROC curve analysis to assess its diagnostic value.

Results: PDZK1 was upregulated in HGG patients and predicted poor overall survival and progression-free survival. Moreover, PDZK1 expression distinguished grade III from grade IV HGG. PDZK1 expression was positively correlated with K, and v, and negatively correlated with k, and k.

Conclusion: PDZK1 is upregulated in HGG, predicts poor survival, and differentiates tumor grading in HGG patients. PDZK1 expression is correlated with DCE-MRI perfusion parameters.

References

Pike M, Stoops C, Langford C, Akella N, Nabors L, Gillespie G . High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magn Reson Med. 2009; 61(3):615-25. PMC: 3243360. DOI: 10.1002/mrm.21931. View

Li H, Zhang B, Liu Y, Yin C . EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway. Med Oncol. 2014; 31(9):162. DOI: 10.1007/s12032-014-0162-x. View

Arevalo-Perez J, Kebede A, Peck K, Diamond E, Holodny A, Rosenblum M . Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas. J Neuroimaging. 2015; 26(3):366-71. PMC: 5510484. DOI: 10.1111/jon.12320. View

Jia Z, Geng D, Xie T, Zhang J, Liu Y . Quantitative analysis of neovascular permeability in glioma by dynamic contrast-enhanced MR imaging. J Clin Neurosci. 2012; 19(6):820-3. DOI: 10.1016/j.jocn.2011.08.030. View

Jain K, Sahoo P, Tyagi R, Mehta A, Patir R, Vaishya S . Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI. Clin Radiol. 2015; 70(10):1128-35. DOI: 10.1016/j.crad.2015.06.076. View

Leach M, Morgan B, Tofts P, Buckley D, Huang W, Horsfield M . Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol. 2012; 22(7):1451-64. DOI: 10.1007/s00330-012-2446-x. View

Russell S, Elliott R, Forshaw D, Golfinos J, Nelson P, Kelly P . Glioma vascularity correlates with reduced patient survival and increased malignancy. Surg Neurol. 2009; 72(3):242-6. DOI: 10.1016/j.surneu.2008.11.012. View

Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A . Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol. 2008; 29(8):1505-10. PMC: 8119049. DOI: 10.3174/ajnr.A1121. View

Kim H, Abd Elmageed Z, Davis C, El-Bahrawy A, Naura A, Ekaidi I . Correlation between PDZK1, Cdc37, Akt and breast cancer malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37. Mol Med. 2014; 20:270-9. PMC: 4107102. DOI: 10.2119/molmed.2013.00166. View

10.

Heye T, Merkle E, Reiner C, Davenport M, Horvath J, Feuerlein S . Reproducibility of dynamic contrast-enhanced MR imaging. Part II. Comparison of intra- and interobserver variability with manual region of interest placement versus semiautomatic lesion segmentation and histogram analysis. Radiology. 2012; 266(3):812-21. DOI: 10.1148/radiol.12120255. View

11.

Saraswathy S, Crawford F, Lamborn K, Pirzkall A, Chang S, Cha S . Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol. 2008; 91(1):69-81. PMC: 3022437. DOI: 10.1007/s11060-008-9685-3. View

12.

Yoo R, Choi S, Kim T, Park C, Park S, Won J . Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. Eur Radiol. 2016; 27(8):3156-3166. DOI: 10.1007/s00330-016-4692-9. View

13.

Arevalo-Perez J, Peck K, Young R, Holodny A, Karimi S, Lyo J . Dynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of Gliomas. J Neuroimaging. 2015; 25(5):792-8. PMC: 5525149. DOI: 10.1111/jon.12239. View

14.

Leach M, Brindle K, Evelhoch J, Griffiths J, Horsman M, Jackson A . The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer. 2005; 92(9):1599-610. PMC: 2362033. DOI: 10.1038/sj.bjc.6602550. View

15.

Law M, Young R, Babb J, Peccerelli N, Chheang S, Gruber M . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008; 247(2):490-8. PMC: 3774106. DOI: 10.1148/radiol.2472070898. View

16.

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

17.

Jia Z, Geng D, Liu Y, Chen X, Zhang J . Low-grade and anaplastic oligodendrogliomas: differences in tumour microvascular permeability evaluated with dynamic contrast-enhanced magnetic resonance imaging. J Clin Neurosci. 2013; 20(8):1110-3. DOI: 10.1016/j.jocn.2012.09.019. View

18.

Guo L, Jiang W, Quan L, Teng X, Zhao J, Qiu H . Mechanism of PDZK1 in Hepatocellular Carcinoma Complicated with Hyperuricemia. J Oncol. 2022; 2022:1403454. PMC: 9678461. DOI: 10.1155/2022/1403454. View

19.

OConnor J, Jayson G . Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?. Clin Cancer Res. 2012; 18(24):6588-98. DOI: 10.1158/1078-0432.CCR-12-1501. View

20.

Mills S, Patankar T, Haroon H, Baleriaux D, Swindell R, Jackson A . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. AJNR Am J Neuroradiol. 2006; 27(4):853-8. PMC: 8133992. View